Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
374 ARTÍCULOS , VIENDO DEL 76 AL 90
Editorial (Thematic Issue: Hybrid Compounds as Multitarget Agents in Medicinal Chemistry - Part II)
Scotti L, Mendonça-Junior FJ, Scotti MT.
Curr Top Med Chem. 2017;17(9):957-958. doi: 10.2174/156802661709170213205211.
Gonzalez B, Abud EM, Abud AM, Poon WW, Gylys KH.
Neurol Clin. 2017 May;35(2):175-190. doi: 10.1016/j.ncl.2017.01.001.
Calcitonin gene-related peptide (CGRP): A novel target for Alzheimer's disease
Singh Y, Gupta G, Shrivastava B, Dahiya R, Tiwari J, Ashwathanarayana M, Sharma RK, Agrawal M, Mishra A, Dua K.
CNS Neurosci Ther. 2017 Jun;23(6):457-461. doi: 10.1111/cns.12696. Epub 2017 Apr 17.
Fessel WJ.
Am J Alzheimers Dis Other Demen. 2017 May;32(3):166-181. doi: 10.1177/1533317517698790. Epub 2017 Mar 17.
Mechanisms of vascular disease in dementia: what does industry want to know?
Wren PB, Hill D, Lockhart A.
Clin Sci (Lond). 2017 May 1;131(9):799-802. doi: 10.1042/CS20160724.
Sawikr Y, Yarla NS, Peluso I, Kamal MA, Aliev G, Bishayee A.
Adv Protein Chem Struct Biol. 2017;108:33-57. doi: 10.1016/bs.apcsb.2017.02.001. Epub 2017 Mar 22.
Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts
Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy BI, Rabinovici GD, Miller BL, Kramer JH, Scheltens P, van der Flier WM; German Dementia Competence Network; University of California San Francisco Memory and Aging Center; Amsterdam Dementia Cohort.
Alzheimers Dement. 2017 Nov;13(11):1226-1236. doi: 10.1016/j.jalz.2017.03.002. Epub 2017 Apr 17.
Shevtsova EF, Vinogradova DV, Neganova ME, Avila-Rodriguez M, Ashraf GM, Barreto GE, Bachurin SO, Aliev G.
CNS Neurol Disord Drug Targets. 2017;16(6):677-685. doi: 10.2174/1871527316666170424114444.
Nazıroğlu M, Muhamad S, Pecze L.
Expert Rev Clin Pharmacol. 2017 Jul;10(7):773-782. doi: 10.1080/17512433.2017.1324781. Epub 2017 May 16.
Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease
Xie J, Wang H, Lin T, Bi B.
Biomed Res Int. 2017;2017:2986460. doi: 10.1155/2017/2986460. Epub 2017 Apr 3.
The Exceptional Vulnerability of Humans to Alzheimer's Disease
Walker LC, Jucker M.
Trends Mol Med. 2017 Jun;23(6):534-545. doi: 10.1016/j.molmed.2017.04.001. Epub 2017 May 5.
Dysregulated Metabolism of the Amyloid-β Protein and Therapeutic Approaches in Alzheimer Disease
Kikuchi K, Kidana K, Tatebe T, Tomita T.
J Cell Biochem. 2017 Dec;118(12):4183-4190. doi: 10.1002/jcb.26129. Epub 2017 Jun 9.
Emerging amyloid and tau targeting treatments for Alzheimer's disease
Khan A, Corbett A, Ballard C.
Expert Rev Neurother. 2017 Jul;17(7):697-711. doi: 10.1080/14737175.2017.1326819. Epub 2017 May 19.
Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets
Khan A, Corbett A, Ballard C.
Expert Rev Neurother. 2017 Jul;17(7):683-695. doi: 10.1080/14737175.2017.1326818. Epub 2017 May 18.
Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease
Knez D, Sova M, Košak U, Gobec S.
Future Med Chem. 2017 May;9(8):811-832. doi: 10.4155/fmc-2017-0036. Epub 2017 May 15.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.